Peter Moran
General Partner @ DCM Ventures
San Francisco, United States
Peter Moran is a Member of the Board of Directors at Iterative Scopes. He attended Stanford University, Massachusetts Institute of Technology, MIT - Sloan School of Management, and Stanford University.
- Total investments:
- 39
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Peter Moran invests in
Stages Peter Moran invests in
Countries Peter Moran invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $4.3M–$16M
- Series B
- $10M–$30M
- Series C
- $15M–$630M
Investment Focus
Industry
- Health Care 5 (13%)
- Semiconductor 4 (10%)
- Medical 3 (8%)
- Electronics 3 (8%)
- Manufacturing 3 (8%)
Stage
- Series B 8 (21%)
- Series C 7 (18%)
- Series A 4 (10%)
- Seed 3 (8%)
- Funding Round 2 (5%)
Country
- United States 17 (44%)
- China 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sound Health uses acoustic resonance to provide nasal relief. Its current product is an app that scans the face to map the bone structure and then a headband that plays music at personalized frequencies for 10 minutes. The headband is off the shelf and the sound levels are akin to wearing earpods. It envisions the headband to be over-the-counter(OTC) so it’s easily accessible to patients, whether prescribed by doctors or not. | $7M / Seed / Jul 24, 2024 | ||
| Queer Spaces is building SPACES, a group chat platform for queer communities, and an app to serve the entirety of the LGBTQ+ spectrum. It’s a place for all queer people to connect over their favourite topics and interests, plan meetups and hang out. They can discover and join specific communities, fandoms, local teams and organizations, and closefriends, some public and others invite-only, all on a platform where they can safely be their true, authentic selves. | $1.1M / Convertible Note / Nov 09, 2022 | ||
| GPx is a biotech company that revolutionizes remote chronic disease management with bloodless blood tests. It is dedicated to transforming the standard of care of cardiorenal diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care.The company was founded in 2020and is based in Boston, Massachusetts. | $3.3M / Seed / Sep 30, 2022 | ||
| Hava is a pre-clinical stage health company with a singular mission to reduce smoking-related illness and death. | $1.7M / Pre-Seed / Nov 13, 2019 | ||
| Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $19M / Series B / Oct 24, 2019 | ||
| Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $23M / Venture - Series Unknown / Dec 08, 2016 | ||
| RayVio Corp. is an advanced health and hygiene company that delivers clean water and environments. RayVio helps protect billions from germs and creates new markets and revenue streams by enabling a new class of products. Its powerful and efficient UV LED technology can be integrated into a variety of applications, powering versatile on-demandsolutions that give consumers control over health without chemicals or costly consumables. To learn more, please visit www.rayvio.com. | $26M / Series B / Apr 26, 2016 | ||
| Augmedix empowers clinicians in all care settings to connect with patients by liberating them from administrative burden through the power of ambient AI, data, and trust.The platform transforms natural conversations into organized medical notes, structured data, and point-of-care notifications that enhance efficiency and clinical decisionsupport.Incorporating data from millions of interactions, Augmedix collaborates with hospitals and health systems to improve clinical, operational, and financial outcomes. | $17M / Venture - Series Unknown / Apr 25, 2016 | ||
| The Athos mission is to help athletes train more effectively and reach their performance goals faster. Athos does this by bringing together the most relevant data and exercise science to deliver simple, actionable insights that allow coaches and athletes to get the most out of their training. | $35M / Series C / Nov 18, 2015 | ||
| The Athos mission is to help athletes train more effectively and reach their performance goals faster. Athos does this by bringing together the most relevant data and exercise science to deliver simple, actionable insights that allow coaches and athletes to get the most out of their training. | $35M / Series C / Nov 18, 2015 | ||
| See all 39 investments → | |||
Co-Investors
About DCM Ventures
DCM Ventures assists entrepreneurs in building companies that will change how institutions and people use and live with technology. DCM Ventures focuses on the size of its team, the money they raise, and the investments they make all so that it can focus on the business of helping portfolio companies succeed. Collectively, the DCM investing partners have over a century of investing and operational experience and each DCM partner has experience building hyper-growth startups into billion-dollar businesses. DCM Ventures manages ten funds totaling $4.0 billion and has made investments in more than 400 technology companies across the United States and Asia. With offices in Silicon Valley, Beijing, and Tokyo, DCM provides hands-on operational guidance and a vast network of global business and financial resources to its portfolio companies.
DCM Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Weijin Huang
Principal
|
|||
David K. Chao
Co-Founder & General Partner
|
|||
Dixon Doll
Co-Founder & Partner Emeritus
|
|||
Frank Lin
Co-Founder and General Partner
|
|||
Ibrahim AlSuwaidi
Principal & Investor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Peter Moran invest in?
Peter Moran invests primarily in Health Care, Semiconductor and Medical startups, most often at Series B and Series C stage. Most of the 39 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Peter Moran invest in?
Peter Moran typically joins rounds of $4.3M–$16M at Series A, $10M–$30M at Series B and $15M–$630M at Series C. These are whole funding-round sizes, not Peter Moran's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Peter Moran took part in.
How do I contact Peter Moran?
Public channels for Peter Moran include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Peter Moran last invest?
The most recent investment recorded for Peter Moran closed in Jul 2024. Shizune tracks 39 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
